Intersect ENT - About the company
Intersect ENT is an acquired company based in Menlo Park (United States), founded in 2003. It operates as a Developer of drug releasing implant to treat sinusitis. Intersect ENT has raised $76.5M in funding from investors like USVP, Medtronic and Norwest. The company has 49 active competitors, including 16 funded and 14 that have exited. Its top competitors include companies like Theradaptive, Regentis Biomaterials and Tivic Health.
Company Details
Developer of a drug-releasing implant to treat sinusitis. The company has developed drug-releasing implants called CE marked and FDA-approved dissolvable implants for the treatment of chronic sinusitis called Propel, Propel Mini and PROPEL Contour. The devices consist of a spring-like implant that expands to open the ethmoid sinus and dissolves to deliver corticosteroids with anti-inflammatory properties to the sinus lining. The company claims that the device is clinically proven to prevent obstruction of the ethmoid sinus following surgery.
- Website
- intersectent.com
- Social
- Phone Number
- +1 **********
- Registered Address
- Menlo Park, California
Key Metrics
Founded Year
2003
Location
Menlo Park, United States
Stage
Acquired
Total Funding
$76.5M in 4 rounds
Latest Funding Round
Ranked
2nd among 49 active competitors
Annual Revenue
$107M as on Dec 31, 2021
Employee Count
73 as on Apr 30, 2026
Similar Companies
Exit Details
Acquired by Medtronic (Aug 06, 2021)
Legal entities associated with Intersect ENT
Intersect ENT is associated with 2 legal entities given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
INTERSECT ENT, INC. CIN: 1271214 , United States, Active | Oct 05, 2003 | $107M (As on Dec 31, 2021) | - | - |
Intersect Ent Inc. CIN: 200280837 , United States, Active | Dec 31, 1999 | - | 371 (As on Dec 31, 2021) | - |
Intersect ENT's acquisition details
Intersect ENT got acquired by Medtronic on Aug 06, 2021.
Click here to take a look at Intersect ENT's acquisition in detail
Sign up to download Intersect ENT's company profile
Intersect ENT's funding and investors
Intersect ENT has raised a total funding of $76.5M over 4 rounds. Its first funding round was on Nov 08, 2010. Its latest funding round was a Post IPO round on May 11, 2020 for $*****. 1 investor participated in its latest round. Intersect ENT has 14 institutional investors.
Here is the list of recent funding rounds of Intersect ENT:
Filter this list
Filter this listDate of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
May 11, 2020 | 8052924 | Post IPO | 1793282 | 2773806 | 1851068 | 5132027 |
Mar 26, 2013 | 8129462 | Series D | 7955952 | 9575339 | 1469155 | |
Sep 01, 2011 | 5185591 | Series C | 2559080 | 2436703 | 5400815 |
Access funding benchmarks and valuations. Sign up today!View details of Intersect ENT's funding rounds and investors
Intersect ENT's founders and board of directors
Founder? Claim ProfileIntersect ENT's employee count trend
Intersect ENT has 73 employees as of Apr 26. Here is Intersect ENT's employee count trend over the years:
Uncover Intersect ENT's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Intersect ENT's Competitors and alternates
Top competitors of Intersect ENT include Theradaptive, Regentis Biomaterials and Tivic Health. Here is the list of Top 10 competitors of Intersect ENT, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Theradaptive 2004, Boston (United States), Series A | Developer of protein engineering technology creating targeted therapeutics for tissue repair | $50M | 64/100 | |
2nd | Intersect ENT 2003, Menlo Park (United States), Acquired | Developer of drug releasing implant to treat sinusitis | $76.5M | 54/100 | |
3rd | Regentis Biomaterials 2004, Or Akiva (Israel), Public | Biodegradable hydrogels for tissue regeneration. | $25M | 56/100 | |
4th |  Tivic Health 2016, Menlo Park (United States), Public | Developer of a bioelectronic medical device for the treatment of sinusitis | $8M | 55/100 | |
5th |  Vivani 2009, Emeryville (United States), Public | Developer of a drug delivery medical device for diabetes | - | - | 54/100 |
6th |  Re-Vana Therapeutics 2015, Belfast (United Kingdom), Series A | Developer of drug delivery platform forophthalmic diseases | $16.7M | 50/100 | |
7th |  Entellus Medical 2006, Plymouth (United States), Acquired | Developer of suite of products for treating chronic sinusitis | $90.5M | 48/100 | |
8th | Innocoll 1985, Philadelphia (United States), Acquired | qaw | $52.9M | 48/100 | |
9th |  Atossa Therapeutics 2009, Seattle (United States), Public | Developer of drugs for treating breast cancer | $6.77M | 47/100 | |
10th | MyPurMist 2001, Concord (United States), Seed | Natural steam inhalers and air purifiers for respiratory relief | $8.89M | 47/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Intersect ENT's competitors? Click here to see the top ones
Intersect ENT's Investments and acquisitions
Intersect ENT has made no investments or acquisitions yet.
News related to Intersect ENT
Filter this list•
Cutera® Appoints Jeryl L. Hilleman to Board of DirectorsBusiness Wire•Jun 11, 2024•Cutera, Intersect ENT
•
•
iRhythm Technologies Adds Two to its Executive Leadership TeamMedical Product Outsourcing•Aug 31, 2022•iRhythm Tech, Dexcom, Intersect ENT
•
•
Intersect ENT gains after receiving U.S. antitrust approval for sale to MedtronicSeeking Alpha•May 10, 2022•Intersect ENT, Medtronic
•
Medtronic is said planning to close Intersect ENT deal this monthSeeking Alpha•Apr 02, 2022•Medtronic, Intersect ENT
•
Intersect ENT to divest business in effort to gain antitrust approval for Medtronic dealSeeking Alpha•Mar 24, 2022•Intersect ENT
•
Medtronic, Intersect ENT said to finalize divestiture plans to help with antitrust concernsSeeking Alpha•Feb 17, 2022•Medtronic, Intersect ENT
•
Intersect ENT Reports Positive Results in Study of Propel Sinus ImplantMedical Product Outsourcing•Jan 27, 2022•Intersect ENT
•
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Intersect ENT
Explore our recently published companies
- Jumo - India based, Unfunded company
- APL - Wednesbury based, 2022 founded, Funding Raised company
- Boston HealthNet (BHN) Research Collaborative - United States based, 2021 founded, Funding Raised company
- PS Digital - Chicago based, 2025 founded, Unfunded company
- Innovation Investment Capital - Cardiff based, 2022 founded, Unfunded company
- North Staffs Tyre & Battery - Newcastle-under-lyme based, 2021 founded, Acquired company
